TLR9 and COVID-19: Taken together, the relatively high numbers of CpG-motifs in SARS-CoV2 and the upstream position of TLR9 in the inflammatory cascades and the broad expression of TLR9 on different cell types that play crucial roles in clinical COVID-19 presentation (Th1 cells, Th17 cells, B cells, neutrophils, platelets), TLR9 is positioned be a promising systemic therapeutic target to dampen or perhaps even prevent the thrombotic complications and so called cytokine storm or hyperinflammatory syndrome in certain specific patients that are suffering from severe COVID-19.